Short answer
Vanda Pharmaceuticals Inc. (VNDA) filed an 8-K current report with the SEC on April 22, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item EX-99.1 (Exhibit EX-99.1). Board expanded from six to seven directors; Charles C. Duncan appointed Class II director through 2026 annual meeting.
Vanda Pharmaceuticals Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Board expanded from six to seven directors; Charles C. Duncan appointed Class II director through 2026 annual meeting
- Independent director under SEC and Nasdaq rules, strengthening board oversight
- Initial restricted stock unit award valued at $390,000, vesting in four equal annual installments
- Annual $50,000 cash fee plus $260,000 restricted stock unit award after each annual meeting
- Equity awards fully vest upon a change of control, increasing transaction-related compensation obligations
Item EX-99.1 · Exhibit EX-99.1
- Charles Duncan appointed director effective April 22, 2026
- Board expands to seven directors, including six independent members
- Duncan brings nearly three decades of biotechnology equity research experience, focused on neurology and psychiatry
- Appointment supports pipeline strategy as Vanda cites recent NEREUS™, BYSANTI™, and Fanapt® label expansion
- Management highlights potentially impactful pipeline data expected over the next ~12 months, subject to clinical and regulatory risks
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Vanda Pharmaceuticals Inc. 8-K filings
Get the next VNDA 8-K as it lands
Follow VNDA for push alerts, or ask the research agent what this filing means.